Entering text into the input field will update the search result below

CytoMed Therapeutics: An Innovative Immunology Biotech Company To Watch

Daron Evans profile picture
Daron Evans


  • CytoMed Therapeutics is developing next-generation CAR-T cell therapies from γδ T cells for multiple solid tumor indications.
  • The use of γδ T cells allows CytoMed to generate allogeneic, off-the-shelf cell therapies.
  • By the end of 2024, CytoMed expects to have human data from two programs and pre-clinical data for its most promising program.

Lymphocytes , t cells or cancer cells

Design Cells/iStock via Getty Images

CytoMed Therapeutics (NASDAQ:GDTC)

CytoMed Therapeutics (GDCT, or the Company), a Singapore-based biotechnology company trading on the NASDAQ, is developing multiple gamma delta chimeric antigen receptor T-cell (“γδ CAR-T”) therapeutics for the treatment of cancer. The Company is one of many who

This article was written by

Daron Evans profile picture
Mr. Evans is a private investor who focuses primarily on life science opportunities.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of GDTC either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

I have a very small position, but believe the science is compelling and would add on clinical validation of the platform.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (2)

Enjoyed your article and the clear concise explanations of the underlying science. I wish you would have commented a bit more on the advantage of the electroporation vs viral techniques
Daron Evans profile picture
@TJCJR I will see if I can get someone with more intimate knowledge of that process. As far as I understand, it is an electromechanical method that works well enough. The viral method is probably a high % conversion rate, but involves having to maintain a viral vector cell bank, which is adds costs, quality checks, time, etc. The key, I believe, is that GDTC are trying to K.I.S.S. the process to maintain simplicity and quality at a low cost.
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

About GDTC

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on GDTC

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.